GlassScriptPhysician profile
Annie Lemus Gonzalez
NPI 1881172682
$4,491.79
in general payments reported to CMS, 2019-2025
29 companies · $2,108 in 2025
The $2,108 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $334 · 2023: $561 · 2024: $1,291 · 2025: $2,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,831 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,830.50 |
| Education | $129.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $416.42 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $383.33 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $350.40 | 2021-2025 | Omnipod |
| Lilly USA, LLC | $342.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $338.85 | 2024-2025 | |
| Novo Nordisk INC | $329.33 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Ascensia Diabetes Care US INC. | $307.56 | 2022-2024 | |
| Abbott Laboratories | $258.81 | 2023-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $256.35 | 2023-2025 | Korlym |
| Sequel Med Tech, LLC | $201.07 | 2025 | Twiist |
| Dexcom, INC. | $196.03 | 2021-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $171.24 | 2024-2025 | Tepezza, Evenity, Prolia |
| Madrigal Pharmaceuticals | $149.41 | 2025 | Rezdiffra |
| Cequr Corporation | $102.50 | 2024-2025 | Cequr Simplicity |
| Beta Bionics, INC. | $98.64 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $92.16 | 2024-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.31 | 2022-2025 | Jardiance |
| Mannkind Corporation | $70.03 | 2023-2025 | Afrezza |
| Neurocrine Biosciences, INC. | $61.92 | 2023-2024 | Ingrezza |
| Amneal Pharmaceuticals LLC | $48.74 | 2025 | Unithroid |
| Antares Pharma, INC. | $36.75 | 2024 | Xyosted |
| Alexion Pharmaceuticals, INC. | $34.76 | 2024-2025 | Strensiq |
| Medtronic, INC. | $33.22 | 2023-2024 | Minimed 780g |
| Globus Medical, INC. | $27.46 | 2025 | Omnia |
| Kyowa Kirin, INC. | $27.13 | 2025 | |
| Astellas Pharma US INC | $24.77 | 2025 | Veozah |
| Chiesi USA, INC. | $18.73 | 2024 | Myalept |
| Abbvie INC. | $16.91 | 2025 | |
| Averitas Pharma INC. | $14.32 | 2025 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.